Oncotype DX Not Cost-Effective for Low-Risk Breast Cancer
Incremental cost-effectiveness ratio varies across clinical risk groups, sensitive to patient age
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.